Details for Patent: 8,790,708
✉ Email this page to a colleague
Which drugs does patent 8,790,708 protect, and when does it expire?
Patent 8,790,708 protects NERLYNX and is included in one NDA.
This patent has forty-six patent family members in twenty-two countries.
Summary for Patent: 8,790,708
| Title: | Coated tablet formulations and uses thereof |
| Abstract: | The present invention provides coated tablet formulations comprising neratinib maleate, and improved methods for making such coated tablets. |
| Inventor(s): | Muhammad Ashraf, Mainuddin Mahmud, Chimanlall Goolcharran, Krishnendu Ghosh, Arwinder Singh Nagi |
| Assignee: | Wyeth LLC |
| Application Number: | US13/972,764 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,790,708 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 8,790,708
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY | ⤷ Start Trial | |||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY-STAGE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASED THERAPY | ⤷ Start Trial | |||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,790,708
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 4066821 | ⤷ Start Trial | 301337 | Netherlands | ⤷ Start Trial |
| European Patent Office | 4066821 | ⤷ Start Trial | CA 2025 00028 | Denmark | ⤷ Start Trial |
| European Patent Office | 4066821 | ⤷ Start Trial | C20250029 | Finland | ⤷ Start Trial |
| European Patent Office | 4066821 | ⤷ Start Trial | PA2025531 | Lithuania | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
